To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

UCLA Clinical Updates counselors and other personnel to tailor their reconstructions to the individual oncologic needs of their patients. Routine MRI for Pacemaker Patients Patients with pacemaker or cardioverter defibrillator devices who are referred for MRI at UCLA undergo an extensive evaluation of their cardiovascular health and level of device-dependence. Learn about the Latest Advances from UCLA Pediatric Hem/Onc Clinic Opens in Bakersfield Diagnosis and Treatment of Bladder Cancer UCLA’s Division of Pediatric Hematology & Oncology has opened an outpatient office in Bakersfield to provide care to children, adolescents and young adults with cancer or blood disorders who reside in the Kern County region. Blue-light cystoscopy and narrow-band imaging improve detection and visualization of bladder-cancer tumor boundaries. Tuberous Sclerosis Program UCLA’s program includes both clinical care and research and is among the few in the nation with the resources and expertise to address the complexities of tuberous sclerosis. Women’s Heart Health The UCLA Women’s Cardiovascular Center employs diverse clinical expertise and cutting- edge research to provide the best possible care for women with cardiovascular disease. Brachytherapy to Treat Variety of Cancers UCLA Pediatric Sarcoma Program The multidisciplinary physicians in UCLA’s Pediatric Bone and Soft-Tissue Sarcoma Program are expert in treating this exceptionally challenging disease to ensure the greatest chance for survival. Treating Children with Food Allergies UCLA is one of the few centers to offer double-blind, placebo-controlled food-challenge testing, and the program includes dietitians who are available to offer guidance in maintaining nutritional balance despite dietary restrictions. UCLA Center for Breast Reconstruction High Dose Rate (HDR) brachytherapy delivers a calculated dose of radiation for a more exact amount of time to better target tumors. 3D Mammography Digital breast tomosynthesis provides radiologists with multiple, thin-section images through the breast to increase breast-cancer detection rates while reducing false-positive results. Pediatric Lupus Care UCLA pediatric rheumatologists and pediatric nephrologists see pediatric lupus patients in a convenient clinic that provides coordination of services, careful diagnosis and close monitoring to control flare-ups and mitigate organ damage. Plastic surgeons in the UCLA Center for Breast Reconstruction work as part of a team alongside breast surgical oncologists, breast medical oncologists, radiation oncologists, wellness UCLA Women’s Cardiovascular Center specializes in meeting women’s unique heart-health needs Each year, heart disease kills more women than men. Some women, particularly those who are relatively young, may be unaware that they have a heart condition. Moreover, a woman’s experience of heart disease is unique and very different from a man’s. The UCLA Women’s Cardiovascular Center employs diverse clinical expertise and cutting- edge research in providing the best possible care for women with cardiovascular disease. Women experience heart disease differently A woman’s symptoms during a heart attack are far more subtle than a man’s and may include not only chest, jaw and back discomfort but also anxiety, sleep disturbances, fatigue and body aches. As a consequence, a woman may ignore or fail to recognize the signs that she is having a heart attack. In addition, women often respond differently than men to medications that are used to treat heart attacks and coronary artery disease. Women are more vulnerable to developing heart-disease risk factors during puberty and pregnancy and more vulnerable to suffering a heart attack or heart disease after menopause. Women who develop gestational hypertension or diabetes have a higher risk of developing heart disease later in life, and they are more likely to die from it. The specialists at the UCLA Women’s Cardiovascular Center work with obstetricians and gynecologists to provide the best care for women at these vulnerable times. UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) UCLAHEALTH.ORG Significant improvements in treating bladder cancer Improved imaging technologies and the evolution of immuno- therapies are transforming bladder cancer to a more manageable disease with lower recurrence rates, says Karim Chamie, MD, MSHS, assistant professor-in- residence of urology at UCLA. “The Barbra Streisand Women’s Heart Health Program enables us to focus on providing educational information and outreach to a number of key groups, including underserved minority communities,” adds Dr. Watson. UCLA’s Bladder Cancer Program provides the latest strategies for diagnosis and treatment of bladder cancer in affiliation with the Institute of Urologic Oncology and UCLA’s Jonsson Comprehensive Cancer Center. Our multidisciplinary team approach allows for specialized perspectives in deciding upon the best option for each individual patient. Fluorescent cystoscopy enhances diagnostic capability A significant challenge is that bladder cancer recurs at higher rates than many other types of cancer. However, two new imaging technologies are now available that are effective in detecting tumors that might not be visible with conventional white-light cystoscopy. UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) 1-844-4UCLADR (1-844-482-5237) stemcellprostatecancer Wrist fractures could predict future breaks Wrist fractures, common among postmenopausal women younger than 65, could predict more serious fractures in other parts of their bodies later in life. Improved stroke recovery UCLA researchers have identified a molecule that, after a stroke, signals brain tissue to form new connections to compensate for the damage and initiate repairs to the brain. New program to solve genetic mysteries UCLA Pediatric Sarcoma Program is one of the nation’s busiest New options for the diagnosis and treatment of bladder cancer Approximately 74,000 Americans are diagnosed with bladder cancer each year. Over the past decade, mortality rates for the disease have declined slightly in women but have remained fairly stable in men. However, recent advances in diagnosis and treatment suggest improved odds for successful treatment in today’s patients. Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have shown that the cells responsible for generating deadly prostate cancer share some genetic qualities with the tissue-specific stem cells that naturally reside in the healthy prostate. The UCLA Barbra Streisand Women’s Heart Health Program is an integral part of the UCLA Women’s Cardiovascular Center. Our program provides community outreach and education to empower women to pursue better cardiovascular health. Community events include lectures and cooking demonstrations to help women understand the risk of heart disease and achieve a healthier lifestyle. “Cardiovascular disease is by far the greatest threat to women’s lives,” explains Karol Watson, MD, director of the UCLA Women’s Cardiovascular Center. “We offer a comprehensive program that includes prevention, education, detection, research — all that contributes to reducing risk.” Prostate-cancer cells have stem-cell qualities To download these and other clinical advances at UCLA Health, go to: UCLA Barbra Streisand Women’s Heart Health Program UCLA physicians and scientists conduct cutting-edge research and are involved in the latest clinical trials aimed at improving cardiovascular diagnosis, treatment, management and care for women with, or at risk for, heart disease. News from UCLA Health “While white-light cystoscopy is capable of identifying 80 to 85 percent of all cancers of the bladder, with the help of narrow- band imaging and blue-light cystoscopy we are able to identify the remaining 15 to 20 percent,” explains Dr. Chamie. UCLA is also home to one of the most robust programs in the nation investigating immunotherapies. “Immunotherapy is the future,” Dr. Chamie explains. “What distinguishes UCLA from other institutions is the number of clinical trials we offer for patients with bladder cancer. Patients are not only getting the standard of care, they are getting care at the cutting edge” Specialized pediatric care for sarcoma patients “The Pediatric Bone and Soft-Tissue Sarcoma Program at UCLA grew out of the recognition that pediatric patients have special needs that require coordination of multiple services,” says Noah Federman, MD, program director, clinical director of Pediatric Hematology & Oncology and associate clinical professor of pediatrics and orthopaedics. “At UCLA, we really understand the need for a devoted pediatric sarcoma program,” he explains. “It is important to have a team of people who can cross age barriers, from infancy to young adulthood.” Pediatric sarcomas are exceptionally challenging diseases that require a dedicated, multidisciplinary treatment approach to ensure the greatest chances of survival. UCLA’s Pediatric Bone and Soft-Tissue Sarcoma Program includes experts in several subspecialty areas and has one of the three busiest clinics in the United States. Pediatric soft-tissue sarcomas are a heterogenous group of malignant tumors that originate from primitive mesenchymal tissue. Sarcomas are diagnosed in about 1,600 children each year in the United States. Five-year survival rate estimates range from 59.2 percent to 68.5 percent, making this illness one of the most life-threatening of all pediatric cancers. Higher survival rates have been associated with treatment at major sarcoma centers. (1) UCLA’s program specializes in all forms of bone and soft-tissue sarcomas, including: • • • • • Ewing sarcoma Osteosarcoma Rhabdomyosarcoma Synovial sarcoma Malignant peripheral nerve sheath tumors • Liposarcoma UCLAHEALTH.ORG 1-800-UCLA-MD1 • Fibrosarcoma • Chondrosarcoma • Aggressive fibromatosis (desmoid tumors) • Undifferentiated soft-tissue sarcomas • Epithelioid sarcoma • Other rare bone and soft-tissue tumors (1-800-825-2631) UCLA is part of an extensive clinical-trials network that offers children and teens the best opportunity for successful recovery through innovative treatments. “We’d like every patient who walks through the door to be part of a clinical trial or registry,” Dr. Federman says. “It is really important to move the ball forward. Because these cancers are so rare, we have to learn from each patient and provide each of them with personalized care.” (1) “Should Soft Tissue Sarcomas Be Treated at High-volume Centers? An Analysis of 4205 Patients,” Juan C. Gutierrez, MD, Eduardo A. Perez, MD, Frederick L. Moffat, MD, Alan S. Livingstone, MD, Dido Franceschi, MD, and Leonidas G. Koniaris, MD, Annals of Surgery, Volume 245, Number 6, June 2007. A new UCLA program offers hope and potential answers for people who have undergone extensive medical testing that has failed to identify their illness.